CompletedPhase 2NCT00390234
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Amit Oza, MDUniversity Health Network-Princess Margaret Hospital
- Intervention
- ziv-aflibercept(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2006 – 2013
Study locations (16)
- City of Hope, Duarte, California, United States
- University of Southern California, Los Angeles, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States
- Peoria Gynecologic Oncology, Peoria, Illinois, United States
- University of Michigan University Hospital, Ann Arbor, Michigan, United States
- Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
- Vancouver General Hospital, Vancouver, British Columbia, Canada
- BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
- London Regional Cancer Program, London, Ontario, Canada
- Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00390234 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.